《公司業績》港華智慧能源(01083.HK)全年純利9.65億元跌23% 派末期息15仙
港華智慧能源(01083.HK)公布截至去年12月底止全年業績,營業額200.73億元,按年升17.2%。純利9.65億元,按年跌23%;每股盈利30.17元。派末期息15仙,上年同期派15仙。
公司公布,去年整體燃氣銷售量增長5%至約152.5億立方米,其中民用售氣量上升8%,佔集團總售氣量20%;工業售氣量則錄得2%的升幅,佔總售氣量51%。分銷售氣量較去年增長14%,佔總售氣量18%,商業售氣量下降4%,佔總售氣量11%。截至去年底總客戶數目達1,593萬戶,年內新增客戶84萬戶。另外截至去年,港華智慧能源共有城市燃氣項目累計183個,年內新增7個項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.